Perspective Therapeutics, Inc.
CATX
$2.16
-$0.03-1.37%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.93% | -15.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.93% | -15.20% | |||
| Cost of Revenue | 22.38% | 23.71% | |||
| Gross Profit | -23.27% | -24.72% | |||
| SG&A Expenses | 0.29% | -1.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.38% | 9.72% | |||
| Operating Income | -15.90% | -10.11% | |||
| Income Before Tax | -18.05% | -21.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.05% | -21.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.87% | -18.20% | |||
| EBIT | -15.90% | -10.11% | |||
| EBITDA | -16.22% | -10.45% | |||
| EPS Basic | -20.77% | -15.21% | |||
| Normalized Basic EPS | -17.98% | -17.96% | |||
| EPS Diluted | -20.77% | -15.21% | |||
| Normalized Diluted EPS | -17.98% | -17.96% | |||
| Average Basic Shares Outstanding | 0.08% | 2.60% | |||
| Average Diluted Shares Outstanding | 0.08% | 2.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||